Navidea Biopharmaceuticals Schedules Fourth Quarter 2018 Earnings Conference Call and Business Update

Conference Call to Take Place March 7, 2019, at 5:00 pm ET

DUBLIN, Ohio–(BUSINESS WIRE)–Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or “the
Company”), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced it will
host a conference call on Thursday, March 7th, 2019, at 5:00
pm ET to discuss its financial results for the fourth quarter of 2018 in
conjunction with the filing of its annual report on Form 10-K.

Jed Latkin, Chief Executive Officer, and Erika Gibson, Director, Finance
and Administration, of Navidea will host the call and provide an update
on recent developments and clinical progress. Management will be
answering questions live immediately following the financial earnings
portion of the conference call.

Conference Call & Webcast Details

Investors and the public are invited to dial into the earnings call
through the conference call number below or participate via the audio
webcast on the company website, www.navidea.com.
Participants who would like to ask questions during the question and
answer session will be prompted by the moderator, who will provide
instructions.

      Event:   Fourth Quarter 2018 Earnings and Business Update Conference Call
Date: Thursday, March 7, 2019
Time: 5:00 pm (Eastern Time)
U.S. & Canada Dial-in: 877-407-0312
Conference ID: 13687788
Webcast Link:

https://webcasts.eqs.com/navidbioph20190307

The recorded conference call can be replayed and will be available for
90 days following the call, available on the investor relations page of
Navidea’s corporate website at www.navidea.com.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea’s Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea’s strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company’s pipeline through global partnering and commercialization
efforts.

For more information, please visit www.navidea.com.

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, among other things: any future
actions by Platinum-Montaur; general economic and business conditions,
both nationally and in our markets; our history of losses and
uncertainty of future profitability; the final outcome of the CRG
litigation in Texas and Ohio; our ability to successfully complete
research and further development of our drug candidates; the timing,
cost and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future financial
performance, financing plans and the impact of competition; our ability
to raise capital sufficient to fund our development and
commercialization programs; our ability to implement our growth
strategy; anticipated trends in our business; advances in technologies;
our ability to comply with the NYSE American continued listing
standards; and other risk factors detailed in our most recent Annual
Report on Form 10-K and other SEC filings. You are urged to carefully
review and consider the disclosures found in our SEC filings, which are
available at www.sec.gov or
at http://ir.navidea.com.

Investors are urged to consider statements that include the words
“will,” “may,” “could,” “should,” “plan,” “continue,” “designed,”
“goal,” “forecast,” “future,” “believe,” “intend,” “expect,”
“anticipate,” “estimate,” “project,” and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

Contacts

Navidea Biopharmaceuticals, Inc.
Jed Latkin, CEO, 614-973-7490
[email protected]

error: Content is protected !!